| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Not well characterized as a therapeutic target; as a nucleoside analog, it may interact with nucleoside transporters, kinases, and polymerases involved in nucleic acid metabolism.
|
|---|---|
| ln Vitro |
In vitro, 6-O-Methyl Guanosine is used as a modified nucleoside in biochemical assays to study nucleic acid structure, base pairing, and enzyme recognition. It may be incorporated into RNA or DNA to investigate the effects of methylation on nucleic acid function. Quantitative bioactivity data is not available in publicly accessible sources.
|
| ln Vivo |
No in vivo activity data is publicly available. As a research reagent, 6-O-Methyl Guanosine is not typically used in animal models for therapeutic purposes.
|
| Enzyme Assay |
No specific cell-free enzyme assay protocol is detailed for 6-O-Methyl Guanosine. For nucleoside analogs, typical cell-free assays include enzyme kinetic studies with purified kinases, polymerases, or methyltransferases using radiolabeled or fluorescent substrates.
|
| Cell Assay |
Cellular activity is assessed in cell lines to study nucleoside uptake, metabolism, and incorporation into nucleic acids. Cells are treated with 6-O-Methyl Guanosine, and endpoints include nucleotide pool analysis (HPLC/MS), nucleic acid incorporation (radiolabeling), and cell viability (MTT assay).
|
| Animal Protocol |
No in vivo animal experimental protocol is publicly available.
|
| ADME/Pharmacokinetics |
Molecular formula: C11H15N5O5 (typical for methylated guanosine); molecular weight: ~297.26. Solubility: soluble in water and DMSO. Storage: typical for nucleosides (desiccated, protected from light, -20°C).
|
| Toxicity/Toxicokinetics |
No toxicity data is publicly available. As a modified nucleoside, standard toxicological studies would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
6-O-Methyl Guanosine is a research-grade compound, not approved for therapeutic use. It is primarily used as a biochemical reagent for nucleic acid research, including studies on RNA methylation, nucleoside analog pharmacology, and nucleic acid structure. No clinical trials have been reported.
|
| Molecular Formula |
C11H15N5O5
|
|---|---|
| Molecular Weight |
297.2673
|
| Exact Mass |
297.107
|
| CAS # |
7803-88-5
|
| PubChem CID |
96312
|
| Appearance |
White to off-white solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Boiling Point |
721.0±70.0 °C at 760 mmHg
|
| Flash Point |
389.9±35.7 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.829
|
| LogP |
-0.58
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
377
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1=NC(=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
|
| InChi Key |
IXOXBSCIXZEQEQ-KQYNXXCUSA-N
|
| InChi Code |
InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7-,10-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~130 mg/mL (~437.31 mM)
H2O : ~2 mg/mL (~6.73 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.5 mg/mL (21.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 65.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.5 mg/mL (21.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 65.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 6.5 mg/mL (21.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3639 mL | 16.8197 mL | 33.6395 mL | |
| 5 mM | 0.6728 mL | 3.3639 mL | 6.7279 mL | |
| 10 mM | 0.3364 mL | 1.6820 mL | 3.3639 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
